Advertisement
Canada markets open in 6 hours 15 minutes

  • S&P/TSX

    21,708.44
    +52.39 (+0.24%)
     

  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • CAD/USD

    0.7270
    +0.0007 (+0.09%)
     

  • CRUDE OIL

    83.70
    +0.97 (+1.17%)
     

  • Bitcoin CAD

    88,964.54
    +4,754.50 (+5.65%)
     

  • CMC Crypto 200

    1,330.67
    +18.04 (+1.37%)
     

  • GOLD FUTURES

    2,402.90
    +4.90 (+0.20%)
     

  • RUSSELL 2000

    1,942.96
    -4.99 (-0.26%)
     

  • 10-Yr Bond

    4.6470
    0.0000 (0.00%)
     

  • NASDAQ futures

    17,426.25
    -121.00 (-0.69%)
     

  • VOLATILITY

    18.00
    0.00 (0.00%)
     

  • FTSE

    7,850.59
    -26.46 (-0.34%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6826
    +0.0005 (+0.07%)
     

Wall Street Fundamentals Releases New In-Depth Stock Reports on ALIM, AUXL, KERX and NKTR

ACCESSWIRE

The Biotech Industry has continued to impress investors with gains in 2014, while the Dow Jones and S&P 500 index sit in the red. The iShares NASDAQ Biotechnology Index ETF (NASDAQ:IBB - News) and the SPDR S&P Biotech ETF (NYSEARCA:XBI - News) have posted gains of 12.68 percent and 20.12 percent, respectively, this year. The industry’s skyrocketing success in recent years has some comparing it to the tech bubble seen in 2000. “You have fundamental news that’s really quite good. Back then (in 2000 for tech) you had a lot of hope, [biotech] has a lot of good fundamental news.” said Mark Lehmann of JMP Securities. Lehmann has also pointed out the consolidation in the market place. “You’re seeing the Pfizer’s (PFE) and Merck’s (MRK) making acquisitions (in biotech) here because they see opportunity, and they don’t see it in their pipeline.”

Alimera Sciences Inc. (NASDAQ:ALIM - News) shares traded in the range of $6.53 to $6.89 Wednesday before settling to close at $6.57, a decrease of 3.81 percent. The stock appears to be facing some resistance at the $8.05and $8.95 levels with some support at $6.47 and $5.81. Shares of Alimera Sciences have gained approximately 40.0 percent year-to-date.

More information on Alimera Sciences and access to the free equity report can be found at:
www.WallStreetFundamentals.com/ALIM

Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL - News) shares traded in the range of $24.66 to $25.26 Wednesday before settling to close at $25.15, an increase of 1.04 percent. The stock appears to be facing some resistance at $26.12 with some support at the $25.14 and $24.20 levels. Shares of Auxilium Pharmaceuticals have gained approximately 20.0 percent year-to-date.

ADVERTISEMENT

More information on Auxilium Pharmaceuticals and access to the free equity report can be found at:
www.WallStreetFundamentals.com/AUXL

Keryx Biopharmaceuticals (NASDAQ:KERX - News) shares traded in the range of $15.21 to $15.55 Wednesday before settling to close at $15.39, an increase of 0.39 percent. The stock appears to be facing some resistance at the $16.18 and $17.96 levels with some support at $14.57 and $13.68. Shares of Keryx Biopharmaceuticals have gained approximately 18.0 percent year-to-date.

More information on Keryx Biopharmaceuticals and access to the free equity report can be found at:
www.WallStreetFundamentals.com/KERX

Nektar Therapeutics (NASDAQ:NKTR - News) shares traded in the range of $13.34 to $13.69 Wednesday before settling to close at $13.49, an increase of 0.90 percent. The stock appears to be facing some resistance at the $13.98 and $14.44 levels with some support at $13.19 and $12.98. Shares of Nektar Therapeutics have gained approximately 18.0 percent year-to-date.

More information on Nektar Therapeutics and access to the free equity report can be found at:
www.WallStreetFundamentals.com/NKTR

Wall Street Fundamentals offers our members a full range of investor services including in-depth equity reports on your favorite companies and timely market updates featuring the hottest stocks trending in the marketplace.

Activate your always free membership by signing up at www.WallStreetFundamentals.com today.

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Wall Street Fundamentals has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Wall Street Fundamentals
Website: www.WallStreetFundamentals.com
Email: editor@wallstreetfundamentals.com